Summary
81 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 27 USD is left as net profit.
- Earnings per share grew by 20% a year over the last 3 years.
- It earns 20 USD a year on every 100 USD of invested capital.
- It has no debt and holds $59.1M in cash.
What to watch
- The share price is above the Bulios Fair Price.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensivePrice against the Bulios Fair Price
P/E against its own last 5 years
P/E against the industry (Medical - Devices)
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 49.6 USD for 1 USD of yearly profit. Over the last five years it was 43.5 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 21% a year over 5 years. Over the last 3 years it grew by 16% a year. Earnings per share grew by 20% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 24 USD
- Research and development 3.6 USD
- Sales and administration 40 USD
- Taxes and other 5.2 USD
- Net profit 27 USD
Net profit, industry median (Medical - Devices) 24 USD
Out of every 100 USD of revenue, 27 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt has no debt.
Financial health in detailDoes it pay a dividend?
Small, stretched- Yield
- 1.42%
- Paid out of profit
- 70%
- Raised in a row
- 1 year
You receive $0.77 per share a year. The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 2
- Hold 0
- Sell 0
Today's price within the analysts' price targets
The average target of $100 is 12% above today's price. 100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- MRI Compatible Patient Vital Signs Monitoring Systems 100%
By region
- UNITED STATES 84%
- International 16%
MRI Compatible Patient Vital Signs Monitoring Systems brings in 100% of revenue.
Segments in detail